Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Goodwill & Intangibles: 2011-2025

Historic Goodwill & Intangibles for RedHill Biopharma (RDHL) over the last 12 years, with Jun 2025 value amounting to $28.3 million.

  • RedHill Biopharma's Goodwill & Intangibles rose 249.48% to $28.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $28.3 million, marking a year-over-year increase of 249.48%. This contributed to the annual value of $5.5 million for FY2024, which is 0.56% down from last year.
  • According to the latest figures from Q2 2025, RedHill Biopharma's Goodwill & Intangibles is $28.3 million, which was up 410.51% from $5.5 million recorded in Q4 2024.
  • RedHill Biopharma's 5-year Goodwill & Intangibles high stood at $89.4 million for Q4 2021, and its period low was $5.5 million during Q4 2024.
  • In the last 3 years, RedHill Biopharma's Goodwill & Intangibles had a median value of $6.4 million in 2023 and averaged $10.1 million.
  • Its Goodwill & Intangibles has fluctuated over the past 5 years, first soared by 10,445.59% in 2021, then crashed by 93.76% in 2023.
  • RedHill Biopharma's Goodwill & Intangibles (Quarterly) stood at $89.4 million in 2021, then remained steady at $89.4 million in 2022, then tumbled by 93.76% to $5.6 million in 2023, then declined by 0.56% to $5.5 million in 2024, then skyrocketed by 249.48% to $28.3 million in 2025.
  • Its last three reported values are $28.3 million in Q2 2025, $5.5 million for Q4 2024, and $8.1 million during Q2 2024.